
When spider webs unite, can tie up a lion.
— Ethiopian proverb.

When spider webs unite, can tie up a lion.
— Ethiopian proverb.
Overview of my articles dedicated to AI startups and investors in the drug discovery and preclinical phase, as well as in the data aggregation process of the entire drug development process

Drug development is the process of bringing a new pharmaceutical drug to the market once a lead compound has been identified through the process of drug discovery (in vitro). After drug discovery the drug candidate enters the preclinical phase where research is done on microorganisms and animals (in vitro and in vivo studies). If the preclinical phase is successful, filing for regulatory status follows — such as via the United States Food and Drug Administration — for an investigational new drug to initiate clinical trials on humans and may include the step of obtaining regulatory approval with a new drug application to market the drug.
For every 10000 compounds screened in drug discovery, approximately 250 compounds will pass through to more rigorous preclinical studies. Eventually, 5 compounds of these 250 will pass to highly regulated clinical trials (Phase1–3). Excluding cancer drugs from the results — which made up fully 31% of all drug programs studied and have overall success rates 5.1% —the overall success rate of all other drugs that enter Phase 1 clinical trials and ultimately reaching FDA approval is 11,9%. The entire process of drug development takes 10 to 15 years and $2.6 billion to bring a drug to market.
Nowadays once a target has been identified and characterised during discovery, what usually follows is bioinformatic predictions, combinatorial chemistry, high-throughput screening, virtual screening and a lot of in silico studies (and in vitro studies). Of course data driven startups are dominating right now the entire process of drug development from drug discovery to preclinical and clinical phase.
So, the first part of this blog is an overview of my articles dedicated to AI startups and investors in the drug discovery and preclinical phase, as well as in the data aggregation process of the entire drug development process.
Thank you for reading
#science #health #pharma #drugdiscovery #AI



Marina has a PhD in molecular and cellular biology and has strong experience in academia, startups and multinationals. She loves science and the sea.